Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Cancer. 2017 Apr 3;123(15):2955–2964. doi: 10.1002/cncr.30690

Table 3:

Distribution of the patients according to Thyroglobulin doubling time and structural doubling time (midDT) groups

DT groups Tg DT status n = 79 patients midDT status n = 88 patients
≤ 1 year 31 (39%) 16 (18%)
1–2 years 14 (18%) 19 (22%)
2–3 years 5 (6%) 11 (12%)
3–4 years 4 (5%) 8 (9%)
≥ 4 years 10 (13%) 16 (18%)
 Negative value 15 (19%) 18 (21%)